292 related articles for article (PubMed ID: 31597834)
1. [New therapeutic agents for acute myeloid leukemia].
Hosono N
Rinsho Ketsueki; 2019; 60(9):1108-1119. PubMed ID: 31597834
[TBL] [Abstract][Full Text] [Related]
2. New drugs approved for acute myeloid leukaemia in 2018.
Kucukyurt S; Eskazan AE
Br J Clin Pharmacol; 2019 Dec; 85(12):2689-2693. PubMed ID: 31469910
[TBL] [Abstract][Full Text] [Related]
3. Venetoclax-based therapies for acute myeloid leukemia.
Guerra VA; DiNardo C; Konopleva M
Best Pract Res Clin Haematol; 2019 Jun; 32(2):145-153. PubMed ID: 31203996
[TBL] [Abstract][Full Text] [Related]
4. Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemia.
Griffiths EA; Carraway HE; Chandhok NS; Prebet T
Leuk Res; 2020 Apr; 91():106339. PubMed ID: 32146154
[TBL] [Abstract][Full Text] [Related]
5. Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse?
Estey E; Karp JE; Emadi A; Othus M; Gale RP
Leukemia; 2020 Mar; 34(3):671-681. PubMed ID: 31915366
[TBL] [Abstract][Full Text] [Related]
6. [European approvals: Glasdegib for Acute myeloid leukemia].
Barrière S; Gastaud L
Bull Cancer; 2020 Dec; 107(12):1206-1207. PubMed ID: 33070952
[No Abstract] [Full Text] [Related]
7. Glasdegib for the treatment of adult patients with newly diagnosed acute myeloid leukemia or high-grade myelodysplastic syndrome who are elderly or otherwise unfit for standard induction chemotherapy.
Goldsmith SR; Lovell AR; Schroeder MA
Drugs Today (Barc); 2019 Sep; 55(9):545-562. PubMed ID: 31584572
[TBL] [Abstract][Full Text] [Related]
8. How I treat acute myeloid leukemia in the era of new drugs.
DiNardo CD; Wei AH
Blood; 2020 Jan; 135(2):85-96. PubMed ID: 31765470
[TBL] [Abstract][Full Text] [Related]
9. New directions for emerging therapies in acute myeloid leukemia: the next chapter.
Daver N; Wei AH; Pollyea DA; Fathi AT; Vyas P; DiNardo CD
Blood Cancer J; 2020 Oct; 10(10):107. PubMed ID: 33127875
[TBL] [Abstract][Full Text] [Related]
10. [Incorporation of novel agents into the treatment for acute myeloid leukemia].
Yamauchi T
Rinsho Ketsueki; 2018; 59(10):1988-1996. PubMed ID: 30305501
[TBL] [Abstract][Full Text] [Related]
11. Forsaken Pharmaceutical: Glasdegib in Acute Myeloid Leukemia and Myeloid Diseases.
Feld J; Silverman LR; Navada SC
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e415-e422. PubMed ID: 33547022
[TBL] [Abstract][Full Text] [Related]
12. Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options.
Richardson DR; Green SD; Foster MC; Zeidner JF
Curr Hematol Malig Rep; 2021 Feb; 16(1):97-111. PubMed ID: 33609248
[TBL] [Abstract][Full Text] [Related]
13. An evaluation of glasdegib for the treatment of acute myelogenous leukemia.
Thomas X; Heiblig M
Expert Opin Pharmacother; 2020 Apr; 21(5):523-530. PubMed ID: 32027196
[No Abstract] [Full Text] [Related]
14. New drugs creating new challenges in acute myeloid leukemia.
Tiong IS; Wei AH
Genes Chromosomes Cancer; 2019 Dec; 58(12):903-914. PubMed ID: 30861214
[TBL] [Abstract][Full Text] [Related]
15. Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine.
Nishi R; Shigemi H; Negoro E; Okura M; Hosono N; Yamauchi T
BMC Cancer; 2020 Oct; 20(1):984. PubMed ID: 33046037
[TBL] [Abstract][Full Text] [Related]
16. Is the overall survival for older adults with AML finally improving?
Lancet JE
Best Pract Res Clin Haematol; 2018 Dec; 31(4):387-390. PubMed ID: 30466753
[TBL] [Abstract][Full Text] [Related]
17. Acute myeloid leukemia: How to treat the fit patient over age 75?
Luger SM
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101105. PubMed ID: 31779985
[TBL] [Abstract][Full Text] [Related]
18. What to use to treat AML: the role of emerging therapies.
Thol F
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):16-23. PubMed ID: 34889359
[TBL] [Abstract][Full Text] [Related]
19. Glasdegib for the treatment of acute myeloid leukemia.
Bruzzese A; Martino EA; Labanca C; Mendicino F; Lucia E; Olivito V; Fimognari F; Neri A; Morabito F; Vigna E; Gentile M
Expert Opin Pharmacother; 2023; 24(14):1537-1543. PubMed ID: 37392098
[TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness of glasdegib versus venetoclax combined with low-dose cytarabine in acute myeloid leukemia.
Tremblay G; Daniele P; Bell T; Chan G; Brown A; Cappelleri JC
J Comp Eff Res; 2021 May; 10(7):603-612. PubMed ID: 33733815
[No Abstract] [Full Text] [Related]
[Next] [New Search]
